Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, TSH Biopharm's Enterprise Value is NT$1,297 Mil.
TSH Biopharm's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was NT$236 Mil. Therefore, TSH Biopharm's EV-to-EBIT ratio for today is 5.50.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, TSH Biopharm's Enterprise Value is NT$1,297 Mil.
TSH Biopharm's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was NT$262 Mil. Therefore, TSH Biopharm's EV-to-EBITDA ratio for today is 4.94.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, TSH Biopharm's Enterprise Value is NT$1,297 Mil.
TSH Biopharm's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was NT$1,337 Mil. Therefore, TSH Biopharm's EV-to-Revenue ratio for today is 0.97.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, TSH Biopharm's Enterprise Value is NT$1,297 Mil.
TSH Biopharm's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$129 Mil. Therefore, TSH Biopharm's EV-to-FCF ratio for today is 10.04.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
TSH Biopharm (ROCO:8432) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
TSH Biopharm's current Enterprise Value is NT$1,297 Mil.
TSH Biopharm's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$236 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
TSH Biopharm's current Enterprise Value is NT$1,297 Mil.
TSH Biopharm's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$262 Mil.
TSH Biopharm's current Enterprise Value is NT$1,297 Mil.
TSH Biopharm's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$1,337 Mil.
TSH Biopharm's current Enterprise Value is NT$1,297 Mil.
TSH Biopharm's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$140 Mil.
TSH Biopharm's current Enterprise Value is NT$1,297 Mil.
TSH Biopharm's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$129 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSH Biopharm Enterprise Value Related Terms
TSH Biopharm Enterprise Value Historical Data
* Premium members only.
The historical data trend for TSH Biopharm's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:8432 vs ZTS, UTHR: Enterprise Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, TSH Biopharm's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TSH Biopharm Enterprise Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, TSH Biopharm's Enterprise Value distribution charts can be found below:
* The bar in red indicates where TSH Biopharm's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
TSH Biopharm's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of NT$1,297 Mil mean?
TSH Biopharm (ROCO:8432) has a Enterprise Value of NT$1,297 Mil as of Jul. 15, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on TSH Biopharm and its competitors.
Is TSH Biopharm's Enterprise Value too high?
TSH Biopharm's current Enterprise Value is NT$1,297 Mil. Overall, TSH Biopharm has a GF Score™ of 84/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TSH Biopharm's Enterprise Value compare to ZTS and UTHR?
TSH Biopharm's Enterprise Value of NT$1,297 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Drug Manufacturers company?
A good Enterprise Value depends on the Drug Manufacturers industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on TSH Biopharm and its competitors. TSH Biopharm's current Enterprise Value is NT$1,297 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TSH Biopharm stock overvalued right now?
Based on GuruFocus' analysis, TSH Biopharm (ROCO:8432) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$78.92, compared to a current price of NT$50.20 — trading 36.4% below its estimated fair value. The current Enterprise Value is NT$1,297 Mil. TSH Biopharm's overall GF Score™ is 84/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For TSH Biopharm (ROCO:8432), the current Enterprise Value is NT$1,297 Mil as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TSH Biopharm (ROCO:8432) Overvalued in 2026?
Based on GuruFocus' analysis, TSH Biopharm stock appears to be undervalued.
The current stock price of NT$50.20 is trading 36.4% below its estimated GF Value™ of NT$78.92.
GuruFocus considers TSH Biopharm to be Significantly Undervalued.
Key valuation signals for ROCO:8432:
Enterprise Value: NT$1,297 Mil
GF Value™: NT$78.92 vs. price of NT$50.20 (36.4% below fair value)
No single metric tells the full story. See the ROCO:8432 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TSH Biopharm Corp Ltd is engaged in sale of a variety of pharmaceuticals, chemical drugs and engaged in biotechnology services. The company specializes in the development, manufacture, and marketing of branded drugs for chronic diseases. Key therapeutic areas include cardiovascular, central nervous system, gastroenterology, and severe chronic diseases, alongside precision medicine/genetic testing services .The Company's revenue is earned domestically. It earns majority of its revenue from the sale of Lozenges.
84GF Score
Get the complete analysis for ROCO:8432
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:8432 has been successfully added to your 
